EMD Serono: Patient Enrollment Completed for Cilengitide's Pivotal Phase III Trial CENTRIC
- CENTRIC study evaluating the efficacy and safety of cilengitide, an integrin inhibitor, in the 1st line treatment of glioblastoma patients in combination with standard therapy
ROCKLAND, Mass.--(BUSINESS WIRE)--Jun 9, 2011 - EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today that patient enrollment in the global pivotal Phase III clinical study CENTRICa has been completed. CENTRIC was designed to assess the efficacy and safety of the investigational integrin inhibitor cilengitide in combination with standard treatment in a biomarker-defined subgroup of newly diagnosed patients with glioblastoma (GBM). More than 500 patients have been successfully recruited into this global trial. The primary endpoint of the study is overall survival.
“Completing patient enrollment in the CENTRIC study is a very exciting milestone for us and takes us a step closer to evaluating the efficacy and safety of cilengitide in patients with this aggressive form of brain cancer, an area of high unmet medical need,” said Dr. Oliver Kisker, Senior Vice President for the Global Clinical Development Unit, Oncology at Merck Serono, a division of Merck KGaA, Darmstadt, Germany.
Developed in EMD Serono's own laboratories in scientific collaboration with external partners, cilengitide is the first in a new class of investigational anti-cancer therapies, known as integrin inhibitors, to reach Phase III development. Cilengitide is thought to control tumor growth by working in two ways: through attacking the tumor cells directly in a targeted manner and through starving tumor cells by stopping the formation of new blood vessels that feed the tumor.1 Cilengitide is an investigational agent and has not been approved for commercial distribution.
In Europe, two to three people in 100,000 develop glioblastoma each year.2 In the United States, about three new cases per 100,000 are reported anually.3 Though rare, glioblastoma is the most aggressive form of primary brain tumors and has a poor prognosis in adults with a two-year overall survival rate of 27.2% with standard of care treatment (radiotherapy plus temozolomide).4
About cilengitide's clinical development program
CENTRIC is a randomized Phase III clinical trial assessing the efficacy and safety of the investigational integrin inhibitor, cilengitide, in combination with standard treatment (radiotherapy plus temozolomide, followed by temozolomide maintenance therapy) versus standard treatment alone in newly diagnosed glioblastoma patients with a methylated methylguanine-DNA methyltransferase (MGMT) gene promoter in the tumor tissue. Other exploratory randomized controlled cilengitide trials currently underway include the Phase I/II COREb companion trial investigating cilengitide in newly diagnosed glioblastoma patients with an unmethylated MGMT gene promoter in the tumor tissue, the Phase I/II CERTOc trial in non-small cell lung cancer and the Phase I/II ADVANTAGEd trial in squamous cell carcinoma of the head and neck.
For more information on studies with cilengitide log on to: http://www.clinicaltrials.gov
a. CENTRIC: Cilengitide in combination with temozolomide and radiotherapy in newly diagnosed glioblastoma Phase III randomized clinical trial
b. CORE: Cilengitide in patients with newly diagnosed glioblastoma multiforme and unmethylated MGMT gene promoter
c. CERTO: Cilengitide and cetuximab (Erbitux®) in combination with platinum-based chemotherapy as first-line treatment for patients with advanced non-small cell lung cancer (NSCLC)
d. ADVANTAGE: Cilengitide in combination of different regimens of cisplatin, 5-FU, and cetuximab to evaluate the safety and efficacy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN)
1. Oliveira-Ferrer L, et al. Journal of Experimental & Clinical Cancer Research 2008; 27:86: 1-30.
2. van Rij CM, et al. Pharm World Sci 2005; 27:92-95.
3. CBTRUS (2011). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2007. Available at: http://www.cbtrus.org/2011-NPCR-SEER/WEB-0407-Report-3-3-2011.pdf; last accessed 14 March 2011.
4. Stupp R, et al. Lancet Oncol 2009; 10:459-66.
Cilengitide is currently being developed by EMD Serono. Cilengitide is the first in a new class of investigational anti-cancer therapies called integrin inhibitors in Phase III of development; it is currently being investigated for the treatment of glioblastoma, SCCHN and NSCLC.
Integrins are cell surface receptors that are improperly regulated in many cancer types. This lack of regulation enables them to enhance tumor growth, survival and invasiveness. Integrins are fundamental in the process of angiogenesis (blood vessel growth) – a process that is essential for tumors as it enables them to grow past a finite size.
In addition to the EMD Serono-sponsored studies, the U.S. National Cancer Institute (NCI) is sponsoring a number of clinical trials under a Cooperative Research and Development Agreement (CRADA) with EMD Serono for the development of cilengitide.
About EMD Serono, Inc.
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, is a leader in the US biopharmaceutical arena, integrating cutting-edge science with unparalleled patient support systems to improve people's lives. The company has strong market positions in neurodegenerative diseases, with Rebif® (interferon beta-1a), as well as in endocrinology, with Saizen® (somatropin (rDNA origin) for injection), Serostim® (somatropin (rDNA origin) for injection) and EGRIFTATM (tesamorelin for injection). EMD Serono is a leader in reproductive health, with Gonal-f® (follitropin alfa for injection), Luveris® (lutropin alfa for injection) and Ovidrel® Prefilled Syringe (choriogonadotropin alfa injection). In addition, EMD Serono is growing its expertise and presence in the area of oncology, with more than 10 projects currently in development. With a clear focus on the patient and a leadership presence in the biopharmaceutical industry, EMD Serono's US footprint continues to grow, with more than 1100 employees around the country and fully integrated commercial, clinical and research operations in the company's home state of Massachusetts.
For more information, please visit www.emdserono.com
About Merck KGaA
Merck is a global pharmaceutical and chemical company with total revenues of ‚¬ 9.3 billion in 2010, a history that began in 1668, and a future shaped by more than 40,000 employees in 67 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
Contact: EMD Serono
Posted: June 2011